Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$12.0b

Sarepta Therapeutics Valuation

Is SRPT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SRPT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SRPT ($127.39) is trading above our estimate of fair value ($67.88)

Significantly Below Fair Value: SRPT is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRPT?

Other financial metrics that can be useful for relative valuation.

SRPT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.5x
Enterprise Value/EBITDA-52.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SRPT's PS Ratio compare to its peers?

The above table shows the PS ratio for SRPT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.7x
NTRA Natera
10.3x14.8%US$11.2b
NBIX Neurocrine Biosciences
7.3x13.5%US$13.9b
UTHR United Therapeutics
4.8x7.7%US$11.1b
EXAS Exact Sciences
4.3x11.1%US$10.7b
SRPT Sarepta Therapeutics
9.7x19.5%US$12.0b

Price-To-Sales vs Peers: SRPT is expensive based on its Price-To-Sales Ratio (9.7x) compared to the peer average (6.7x).


Price to Earnings Ratio vs Industry

How does SRPT's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a21.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SRPT is good value based on its Price-To-Sales Ratio (9.7x) compared to the US Biotechs industry average (12.5x).


Price to Sales Ratio vs Fair Ratio

What is SRPT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRPT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.7x
Fair PS Ratio5.4x

Price-To-Sales vs Fair Ratio: SRPT is expensive based on its Price-To-Sales Ratio (9.7x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SRPT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$127.39
US$164.54
+29.2%
14.3%US$224.00US$128.00n/a20
Apr ’25US$128.40
US$164.33
+28.0%
14.1%US$224.00US$128.00n/a21
Mar ’25US$128.67
US$164.42
+27.8%
14.2%US$224.00US$128.00n/a21
Feb ’25US$122.83
US$147.56
+20.1%
20.5%US$224.00US$103.00n/a21
Jan ’25US$96.43
US$135.84
+40.9%
26.4%US$224.00US$80.00n/a20
Dec ’24US$84.44
US$139.22
+64.9%
27.7%US$224.00US$80.00n/a18
Nov ’24US$76.52
US$138.24
+80.7%
30.4%US$220.00US$40.00n/a17
Oct ’24US$121.22
US$181.72
+49.9%
12.6%US$223.00US$139.00n/a18
Sep ’24US$122.51
US$179.47
+46.5%
13.5%US$223.00US$139.00n/a19
Aug ’24US$107.53
US$179.78
+67.2%
13.4%US$221.00US$139.00n/a18
Jul ’24US$114.52
US$178.63
+56.0%
13.1%US$218.00US$139.00n/a19
Jun ’24US$124.28
US$177.70
+43.0%
12.2%US$218.00US$139.00n/a20
May ’24US$125.11
US$171.28
+36.9%
11.4%US$206.00US$139.00n/a18
Apr ’24US$137.83
US$170.44
+23.7%
11.6%US$206.00US$139.00US$128.4018
Mar ’24US$145.63
US$168.84
+15.9%
14.5%US$226.00US$125.00US$128.6719
Feb ’24US$122.36
US$149.44
+22.1%
14.2%US$195.00US$108.00US$122.8318
Jan ’24US$129.58
US$145.95
+12.6%
14.8%US$190.00US$101.00US$96.4320
Dec ’23US$122.98
US$140.10
+13.9%
16.1%US$190.00US$100.00US$84.4420
Nov ’23US$114.08
US$134.15
+17.6%
18.4%US$193.00US$93.00US$76.5220
Oct ’23US$110.54
US$132.05
+19.5%
17.7%US$182.00US$93.00US$121.2220
Sep ’23US$110.08
US$128.65
+16.9%
19.0%US$182.00US$93.00US$122.5120
Aug ’23US$91.55
US$118.65
+29.6%
20.6%US$162.00US$80.00US$107.5320
Jul ’23US$75.71
US$117.25
+54.9%
20.7%US$160.00US$74.00US$114.5220
Jun ’23US$72.60
US$118.10
+62.7%
20.7%US$160.00US$74.00US$124.2820
May ’23US$72.32
US$119.20
+64.8%
22.2%US$183.00US$77.00US$125.1120
Apr ’23US$82.56
US$119.25
+44.4%
22.0%US$183.00US$80.00US$137.8320

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.